Podgrupy pacjentów z zespołem Sjögrena klasyfikowane według obecności autoprzeciwciał – charakterystyka kliniczna i immunologiczna.
Data nadesłania: 21-08-2018
Data ostatniej rewizji: 29-11-2018
Data akceptacji: 29-11-2018
Data publikacji online: 23-12-2018
Data publikacji: 23-12-2018
Reumatologia 2018;56(6):346-353
Sjögren’s syndrome (SS) is an autoimmune disease characterised by heterogeneous clinical presentation and presence of various autoantibodies – anti-SSA/Ro of diagnostic value, less specific anti-SSB/La and others. We searched for biomarker(s) and potential therapeutic target(s) of SS subsets that vary in their autoantibody profile.

Material and methods:
Eighty-one patients with SS (70 female and 11 male) and 38 healthy volunteers (28 female and 10 male) were included in the study. Patients were categorised according to absence (group 1) or presence of anti-SSA/Ro antibody which occurred either alone (group 2) or together with anti-SSB/La (group 3). Clinical evaluation was performed, and presence of autoantibodies and concentrations of cytokines relevant to SS pathogenesis, i.e. a proliferation inducing ligand (APRIL), B-lymphocyte activating factor (BAFF), interleukin (IL) 4, IL-10, interferon  (IFN-) and thymic stromal lymphopoietin (TSLP), in sera were determined.

Frequency of autoantibodies other than anti-SSA/Ro and anti-SSB/La, the number of autoantibody specificities and anti-nuclear antibody titres were higher in group 2 and/or 3 than in group 1 of SS patients. Moreover, SS patients of groups 2 and 3 developed disease symptoms at younger age, and more often had positive Schirmer’s test and skin lesions. In addition, serum concentrations of APRIL, but not other tested cytokines, were significantly higher in the patients of both groups 2 and 3 than those of group 1 and healthy volunteers.

Sjögren’s syndrome patients with signs of B-cell epitope spreading are characterised by early disease onset, more frequent xerophthalmia and skin involvement, and up-regulated serum APRIL level. We suggest that therapeutic neutralisation of APRIL may be beneficial for these patients.

Brito-Zeron P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers 2016; 2: 16047.
Barone F, Colafrancesco S. Sjögren syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol 2016; 34 (Suppl 98): S58-S62.
Ferro F, Marcucci E, Orlandi M, et al. One year in review 2017: primary Sjögren’s syndrome. Clin Exp Rheumatol 2017; 35: 179-191.
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76: 9-16.
Vasiliki-Kalliopi B, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles.
J Autoimmunity 2012; 39: 15-26.
Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjögren’s syndrome. Eur J Clin Invest 2010; 40: 1026-1036.
Theander E, Jonsson R, Sjöström B, et al. Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantobody profiling. Arthritis Rheum 2015; 67: 2427-2436.
Baldini C, Pepe P, Quartuccio L, et al. Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 2014; 53: 839-844.
Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren’s syndrome. Scand J Immunol 2005; 62: 421-428.
Youinou P, Pers JO. Disturbance of cytokine networks in Sjögren’s syndrome. Arthritis Res Ther 2011; 13: 227.
Roeschler N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome: potential therapeutic targets. Ann Rheum Dis 2010; 69: 945-948.
Hillen MR, Kruize AA, Bikker A, et al. Decreased expression of thymic stromal lymphopoietin in salivary glands of patients with primary Sjögren’s syndrome is associated with increased disease activity. Mod Rheumatol 2016; 26: 105-109.
Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology (Oxford) 2018; 57: 921-930.
Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
Cornaby C, Gibbson L, Mayhew V, et al. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol Lett 2015; 163: 56-68.
Kurien BT, Dsouza A, Igoe A, et al. Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren’s syndrome model among multiple strains of inbred mice. Clin Exp Immunol 2013; 173: 67-75.
Hernández-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sjögren’s syndrome. Autoimmunity Rev 2011; 10: 123-125.
Garcia-Carrasco M, Mendoza-Pinto C, Jiménez-Hernández C, et al. Serological features of primary Sjögren’s syndrome: clinical prognostic correlation. Int J Clin Rheumatol 2012; 7: 651-659.
Baer AN, Medrano L, McAdams-DeMarco M, et al. Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sjögren’s syndrome: analysis of the Sjögren’s International Collaborative clinical alliance cohort. Arthritis Care Res 2016; 68: 1554-1559.
Baer AN, Petri M, Sohn J, et al. Association of antibodies to interferon-inducible protein-16 with markers of more severe disease in primary Sjögren’s syndrome. Arthritis Care Res 2016; 68: 254-260.
Quartuccio L, Baldini C, Bartoloni E, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmunity Rev 2015; 14: 1019-1022.
Ramos-Casals M, Cervera R, Font J, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus 1998; 7: 202-206.
Nishiyama S, Miyawaki S, Hashimoto T. Cutaneous manifestations of primary Sjögren’s syndrome. Nihon Rinsho 1995; 53: 2551-2556.
Brito-Zeron P, Retamozo S, Akasbi M, et al. Annular erythema in primary Sjögren’s syndrome: description of non-Asian cases. Lupus 2014; 23: 166-175.
Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 2017; 36: 3-19.
Vosters JL, Roescher N, Polling EJ, et al. The expression of APRIL in Sjögren’s syndrome: aberrant expression of APRIL in the salivary gland. Rheumatology (Oxford) 2012; 51: 1557-1562.
Deng F, Chen J, Zheng J, et al. Association of BAFF and IL-17A with subphenotypes of primary Sjögren’s syndrome. Int J Rheum Dis 2016; 19: 715-720.
Jonsson MV, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. J Clin Immunol 2005; 25: 189-201.
Bootsma H, Kroese FGM, Vissink A. Rituximab in the treatment of Sjögren’s syndrome: is it the right or wrong drug? Arthritis Rheumatol 2017; 69: 1346-1349.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top